Rapid Phenotypic Antibiotic Susceptibility Profiling of Clinical <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Blood Cultures

• Published in: Antibiotics
• Main Authors: Idan Hefetz, Rita Bardenstein, Shahar Rotem, Galia Zaide, Gal Bilinsky, Ohad Shifman, Oren Zimhony, Ronit Aloni-Grinstein
• Format: Article
• Language: English
• Published: MDPI AG 2024-02-01
• Subjects: bloodstream infection; <i>Escherichia coli</i>; <i>Klebsiella pneumoniae</i>; MAPt; antibiotic susceptibility
• Online Access: https://www.mdpi.com/2079-6382/13/3/231

Bloodstream infections (BSI) are defined by the presence of viable bacteria or fungi, accompanied by systemic signs of infection. Choosing empirical therapy based solely on patient risk factors and prior antibiotic susceptibility test (AST) may lead to either ineffective treatment or unnecessarily broad-spectrum antibiotic exposure. In general, Clinical & Laboratory Standards Institute guideline-approved ASTs have a turnaround time of 48–72 h from sample to answer, a period that may result in a critical delay in the appropriate selection of therapy. Therefore, reducing the time required for AST is highly advantageous. We have previously shown that our novel rapid AST method, MAPt (Micro-Agar-PCR-test), accurately identifies susceptibility profiles for spiked bioterrorism agents like <i>Bacillus anthracis</i>, <i>Yersinia pestis</i> and <i>Francisella tularensis</i> directly from whole-blood and blood culture samples, even at low bacterial levels (500 CFU/mL). This study evaluated the performance of MAPt on routine bloodstream infection (BSI), focusing on <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolates from clinical cultures, including resistant strains to some of the six tested antibiotics. Notably, MAPt yielded results exceeding 95% agreement with the standard hospital method within a significantly shorter timeframe of 6 h. These findings suggest significant potential for MAPt as a rapid and reliable BSI management tool.